ArticleJournal of general internal medicine2026
Severity of Gastrointestinal Bleeding in Anticoagulant Therapy with Vitamin K Antagonist or Direct Oral Anticoagulant Therapy.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt remains undetermined whether gastrointestinal bleeding (GIB) associated with direct oral anticoagulant (DOAC) or vitamin K antagonists (VKA) is more severe.
methodsIn Danish nationwide registries, we identified patients with atrial fibrillation (AF) treated with anticoagulation with gastrointestinal bleeding (GIB). Logistic regression models were used to compare GIB severity between DOAC and VKA users, defined by 1. red blood cell transfusion or in-hospital death and 2. endoscopies.
resultsFrom 2012-2018, 6,784 anticoagulated AF patients with GIB were identified; 3,724 patients VKA users and 3,060 DOAC (apixaban, dabigatran or rivaroxaban) users. The proportion of upper GIB was 49% in VKA users and 40.1% in DOAC users. Blood transfusions were administered to 58.2% and 43.8-48.9% of patients with VKA and DOAC, respectively. Odds ratios (OR, adjusted for age, sex, and comorbidities) for severe GIB were significantly reduced for all DOACs compared to VKA (apixaban 0.71 (95% confidence interval (CI) 0.59-0.85), dabigatran 0.64 (95% CI 0.55-0.75) and rivaroxaban 0.69 (95% CI 0.59-0.81)). Odds for endoscopy was significantly reduced in apixaban (OR 0.77 (95% CI 0.65-0.90) and dabigatran (OR 0.81 (95% CI 0.71-0.93) compared to VKA, and borderline reduced for rivaroxaban (OR 0.88 (95% CI 0.77-1.02)). In patients with upper GIB, compared to VKA the use of gastroscopy was significantly reduced for apixaban (0.68 (95% CI 0.53-0.87)) but not for dabigatran or rivaroxaban.
conclusionVKA use was associated with more severe GIB and more frequent endoscopies compared to DOAC. Future studies should identify subgroups at particular risk of severe GIB.
Indexed as
Identifiers
42056366What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.